Biotech

Organon Signs a Licensing Deal with Henlius for Biosimilars Targeting Osteoporosis and Breast Cancer

Global women’s health pharma company Organon has entered into an agreement with Shanghai Henlius Biotech, whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab, HLX11) and Prolia/Xgeva (denosumab, HLX14). Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. Pertuzumab is used for the treatment of certain patients with HER2+ breast cancer in combinations with…

Women’s Health Biotech Company Oviva Raises $11.5M in Seed Funding to Address Ovarian Aging

Women’s health biotech company Oviva Therapeutics has announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5M in seed funding, to develop first-in-class therapeutics to improve healthspan, the period of life spent in good health, in women. Oviva Therapeutics addresses the vast unmet need in women’s health by expanding funding, research, and clinical development of treatments…

Biotech Company Mirvie Raises $60M for Its RNA Platform Focused on Early Prediction of Pregnancy Complications

Mirvie‘s proprietary RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis. It can predict preeclampsia and preterm birth months before they happen by…

Celmatix Reaches a Key Preclinical Milestone in Its Premature Menopause Prevention Drug Program

We last spoke about Celmatix in January, when the company announced that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec has progressed into hit-identification. Now the company is back with more promising news and this time it’s about premature menopause. According to a release Celmatix has identified of a novel AMHR2 agonist compound that has demonstrated…

Renegade.bio and Metabolomic Diagnostics Partner to Develop a Novel Preeclampsia Risk Screening Test

Biotech firm Renegade.bio and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early…

Biotech Company Amyris Gets Serious about the Menopause Market with the Acquisition of Menolabs

Amyris, a synthetic biotech company breaking into Clean Health & Beauty, is getting serious about the menopause market with the acquisition on Menolabs, who have developed line of all natural, proprietary supplements focused on treating perimenopause and menopause symptoms as well as a menopause health tracking app, and a community forum. Amyris previously shared its intention of launching a new consumer brand…

Biotech: All Eyes on Ovarian Health and Biology

Ovarian biology is getting quite a bit of attention lately. And rightfully so given the large potential impact innovation in this space can have on the lives of literally every single woman on this planet. So it truly is about time we spend some time on ovarian health here on this blog, share an overview and some insights into the space with…

Celmatix, Evotec & Bayer Just Hit Another Milestone in Their Quest to Develop a First-in-Class Drug for PCOS

Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, has announced today that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, has progressed into hit-identification. It may still be early in the process, but what this milestone essentially means is that Celmatix, Evotec and pharma leader Bayer, who formed a “PCOS alliance” around…